3,4-Methylenedioxyamphetamine

Identification

Name
3,4-Methylenedioxyamphetamine
Accession Number
DB01509
Type
Small Molecule
Groups
Experimental, Illicit
Description

An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]

Structure
Thumb
Synonyms
  • Tenamfetamine
Categories
UNII
XJZ28FJ27W
CAS number
4764-17-4
Weight
Average: 179.2157
Monoisotopic: 179.094628665
Chemical Formula
C10H13NO2
InChI Key
NGBBVGZWCFBOGO-UHFFFAOYSA-N
InChI
InChI=1S/C10H13NO2/c1-7(11)4-8-2-3-9-10(5-8)13-6-12-9/h2-3,5,7H,4,6,11H2,1H3
IUPAC Name
1-(2H-1,3-benzodioxol-5-yl)propan-2-amine
SMILES
CC(N)CC1=CC2=C(OCO2)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental
AcepromazineAcepromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Acrivastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Acrivastine.Approved
Alcaftadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alcaftadine.Approved
Alfentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlgeldrateAlgeldrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Alimemazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Alphacetylmethadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
Alphaprodine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
AmitriptylineAmitriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Ammonium chlorideThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Antazoline3,4-Methylenedioxyamphetamine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Astemizole3,4-Methylenedioxyamphetamine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AzaperoneAzaperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Vet Approved
Azatadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azatadine.Approved
Azelastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Azelastine.Approved
Bamipine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Bezitramide3,4-Methylenedioxyamphetamine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Brofaromine.Experimental
BromperidolBromperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Brompheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Brompheniramine.Approved
Buclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Buclizine.Approved
Buprenorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Butorphanol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric Acid3,4-Methylenedioxyamphetamine may decrease the sedative activities of Butyric Acid.Experimental
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Carbinoxamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Carbinoxamine.Approved
Carfentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
Cetirizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cetirizine.Approved
Chloropyramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chloropyramine.Approved
Chlorphenamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenamine.Approved
Chlorphenoxamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Withdrawn
Cimetidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cimetidine.Approved
Cinnarizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cinnarizine.Approved
Clemastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Clemastine.Approved
ClomipramineClomipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
ClozapineClozapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Codeine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Cyclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Cyproheptadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
DesipramineDesipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Desloratadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Desloratadine.Approved, Investigational
Dexbrompheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexbrompheniramine.Approved
Dexchlorpheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
Dextromoramide3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
Dextropropoxyphene3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
Dezocine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Dihydrocodeine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
Dihydroetorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
Dihydromorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
Dimenhydrinate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimenhydrinate.Approved
Dimetindene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimetindene.Approved
Dimetotiazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Dimetotiazine.Approved
Diphenhydramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Diphenhydramine.Approved
Diphenoxylate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
DosulepinDosulepin may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Doxepin3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxepin.Approved
Doxylamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPE3,4-Methylenedioxyamphetamine may increase the analgesic activities of DPDPE.Investigational
DroperidolDroperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
Ebastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Emedastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Emedastine.Approved
Epinastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Epinastine.Approved, Investigational
Esmirtazapine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Esmirtazapine.Investigational
Ethopropazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with 3,4-Methylenedioxyamphetamine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Withdrawn
Ethylmorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
Etorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
Famotidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Illicit, Withdrawn
Fentanyl3,4-Methylenedioxyamphetamine may increase the analgesic activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Fexofenadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Flunarizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
Glutamic AcidThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
HarmalineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Harmaline.Experimental
Heroin3,4-Methylenedioxyamphetamine may increase the analgesic activities of Heroin.Approved, Illicit
HydracarbazineHydracarbazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental
Hydrocodone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydrocodone.Approved, Illicit
Hydromorphone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Hydroxyzine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
ImipramineImipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Ioflupane I-1233,4-Methylenedioxyamphetamine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
IproclozideIproclozide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Isothipendyl3,4-Methylenedioxyamphetamine may decrease the sedative activities of Isothipendyl.Approved
Ketobemidone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Ketobemidone.Approved
Ketotifen3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ketotifen.Approved
Lafutidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Lafutidine.Investigational
Lavoltidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Lavoltidine.Investigational
Levocabastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Levocabastine.Approved
Levocetirizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl Acetate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levomethadyl Acetate.Approved
Levorphanol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Levorphanol.Approved
LithiumLithium may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Lodoxamide3,4-Methylenedioxyamphetamine may decrease the sedative activities of Lodoxamide.Approved
Lofentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Loratadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
MagaldrateMagaldrate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
Meclizine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Meclizine.Approved
MelperoneMelperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Meptazinol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Meptazinol.Experimental
Mepyramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
Mequitazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Methadone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadone.Approved
Methadyl Acetate3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
Methapyrilene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Approved
MethenamineThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Investigational
Metiamide3,4-Methylenedioxyamphetamine may decrease the sedative activities of Metiamide.Experimental
Mianserin3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mianserin.Approved
MinaprineMinaprine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Mirtazapine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mirtazapine.Approved
Mizolastine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
MolindoneMolindone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
MoperoneMoperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Morphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Nalbuphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
Nicomorphine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Nicomorphine.Experimental
Nizatidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Nizatidine.Approved
Normethadone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
OctamoxinOctamoxin may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
Olopatadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
OpipramolOpipramol may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Opium3,4-Methylenedioxyamphetamine may increase the analgesic activities of Opium.Approved, Illicit
OsanetantOsanetant may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Oxatomide3,4-Methylenedioxyamphetamine may decrease the sedative activities of Oxatomide.Investigational
Oxycodone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
Oxymorphone3,4-Methylenedioxyamphetamine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Ozagrel3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
PargylinePargyline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Pemirolast3,4-Methylenedioxyamphetamine may decrease the sedative activities of Pemirolast.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Pentazocine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
PerospironePerospirone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Pethidine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Pethidine.Approved
Phenazocine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Phenindamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
Pheniramine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Pheniramine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.Approved
Phenoperidine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
PipamperonePipamperone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Piritramide3,4-Methylenedioxyamphetamine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
ProchlorperazineProchlorperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
Promethazine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
ProtriptylineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Quifenadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Quifenadine.Experimental
RacloprideRaclopride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Ranitidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Remifentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
Roxatidine acetate3,4-Methylenedioxyamphetamine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Withdrawn
Sufentanil3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
SultoprideSultopride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Tapentadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tapentadol.Approved
Terfenadine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Terfenadine.Withdrawn
Tesmilifene3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Investigational
ThiopropazateThiopropazate may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Thonzylamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
TiaprideTiapride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
Tilidine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
Tramadol3,4-Methylenedioxyamphetamine may increase the analgesic activities of Tramadol.Approved, Investigational
Tranilast3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Approved
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Vet Approved
TrimipramineTrimipramine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
Tripelennamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
Triprolidine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Triprolidine.Approved
Tritoqualine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Tritoqualine.Experimental
VeraliprideVeralipride may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental
Vitamin CThe serum concentration of 3,4-Methylenedioxyamphetamine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
ZotepineZotepine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB41931
PubChem Compound
1614
PubChem Substance
46506100
ChemSpider
1555
BindingDB
50005247
ChEBI
100592
ChEMBL
CHEMBL6731
Wikipedia
3,4-Methylenedioxyamphetamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP1.64HANSCH,C & LEO,AJ (1985)
pKa9.67 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility2.83 mg/mLALOGPS
logP1.15ALOGPS
logP1.43ChemAxon
logS-1.8ALOGPS
pKa (Strongest Basic)10.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.48 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity49.47 m3·mol-1ChemAxon
Polarizability19.51 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9668
Caco-2 permeable+0.6011
P-glycoprotein substrateNon-substrate0.7169
P-glycoprotein inhibitor INon-inhibitor0.9117
P-glycoprotein inhibitor IINon-inhibitor0.9278
Renal organic cation transporterNon-inhibitor0.801
CYP450 2C9 substrateNon-substrate0.8661
CYP450 2D6 substrateNon-substrate0.6198
CYP450 3A4 substrateNon-substrate0.6464
CYP450 1A2 substrateInhibitor0.7625
CYP450 2C9 inhibitorNon-inhibitor0.8247
CYP450 2D6 inhibitorInhibitor0.7713
CYP450 2C19 inhibitorNon-inhibitor0.5475
CYP450 3A4 inhibitorNon-inhibitor0.7028
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5
Ames testNon AMES toxic0.6835
CarcinogenicityNon-carcinogens0.8578
BiodegradationReady biodegradable0.6509
Rat acute toxicity2.4882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.9386
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0900000000-ceb833ad1eb42d11bf4a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0900000000-7795b35d40550ca1ea10
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03ei-0900000000-510f32fec3a45da3afe8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a5i-0900000000-5ba589950b29c036e6af
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4r-2900000000-7d9cec73d2dd144096d7
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a6r-4900000000-56ce80af24db379bcf90
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-9500000000-7c78e7d8dc85b9c6aa0d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fba-9200000000-9b312e42e8f1bd38d687
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-9100000000-38f4dd19df31aa785f14

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxoles
Sub Class
Not Available
Direct Parent
Benzodioxoles
Alternative Parents
Aralkylamines / Benzenoids / Oxacyclic compounds / Acetals / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives
Substituents
Benzodioxole / Aralkylamine / Benzenoid / Oxacycle / Acetal / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:10 / Updated on October 02, 2017 04:59